Revolution Medicines (NASDAQ: RVMD) net income
Revolution Medicines reported a net loss of $1,131m for fiscal 2025; in fiscal 2024 it reported a net loss of $600.1m. Earnings per share were −$5.95.
Revolution Medicines's best year of the last 7 was fiscal 2019. It reported a loss in 7 of those 7 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$1,131m | — | — | −$5.95 |
| 2024 | −$600.1m | — | — | −$3.58 |
| 2023 | −$436.4m | — | −3,768.3% | −$3.86 |
| 2022 | −$248.7m | — | −703.0% | −$3.08 |
| 2021 | −$187.1m | — | −636.6% | −$2.57 |
| 2020 | −$108.2m | — | −251.6% | −$2.01 |
| 2019 | −$47.7m | — | −95.2% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Revolution Medicines net income compared with its sector
By net income for its latest fiscal year, Revolution Medicines ranks 494th of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 492nd | Accendra Health | −$1,101m | −39.8% |
| 493rd | Acadia Healthcare | −$1,103m | −33.3% |
| 494th | Revolution Medicines | −$1,131m | — |
| 495th | Quidelortho | −$1,132m | −41.5% |
| 496th | Enovis | −$1,184m | −52.7% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Revolution Medicines
- How much did Revolution Medicines earn in fiscal 2025?
- Revolution Medicines reported a net loss of $1,131m for fiscal 2025. In fiscal 2024 it reported a net loss of $600.1m.
- What are the earnings per share of Revolution Medicines?
- They were −$5.95 in fiscal 2025, compared with −$3.58 in fiscal 2024.
- Where does Revolution Medicines rank in its sector by net income?
- It ranks 494th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Revolution Medicines come from?
- From the annual report (Form 10-K) that Revolution Medicines files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Revolution Medicines files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019. More on Revolution Medicines: the Revolution Medicines page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.